1. National Heart and Lung Institute (NHLI) Cardiovascular Sciences Unit, Hammersmith Hospital, Imperial College London, London, United Kingdom;
2. Silence Therapeutics, Berlin, Germany; and
3. IFOM, The FIRC Institute of Molecular Oncology, Milan, Italy